Article, see p 1935 D egenerative calcific aortic stenosis (AS) is common, affecting >3% in those >65 years of age in the Western world, with a prevalence that will continue to increase as a result of an aging population. 1 The pathophysiology is progressive calcification and restriction of the aortic valve opening, with many similarities to atherosclerotic disease such as inflammation and lipid deposition, as well as activation of pathways leading to osteoblastic differentiation and apoptosis. Left ventricular (LV) pressure overload ensues insidiously, followed by adaptive LV hypertrophy, which helps to reduce wall stress. Although this process can be protracted and asymptomatic for years, the transition to heart failure typically occurs with the development of symptoms. Because medical therapy to halt the progression of AS has not been effective so far, 3 the only definitive treatment is aortic valve replacement (AVR).
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Historically, open surgery with AVR was a high-risk endeavor. It was not uncommon for physicians to wait until the patient was clearly symptomatic and AS was truly severe (ie, gradients >50 mm Hg) in order to offer management with a reasonable risk:benefit ratio. Nowadays, the risk for AVR with either modern surgical techniques or transcatheter methods (ie, transcatheter AVR [TAVR]) has never been lower, with operative mortality for the procedures frequently 1% to 2%. However, despite this low risk, the triggers for AS treatment have not changed significantly over the years and continue to remain centered on symptoms, AS severity, and overt ventricular decompensation. 4, 5 Symptoms are not only subjective but often hard to elicit and can be multifactorial given common comorbidities of aging. The determination of AS severity frequently is not so straightforward with echocardiography. 6 Signs of LV decompensation such as the presence of congestive heart failure or a drop in LV ejection fraction represent an advanced stage of presentation and unfortunately often are not entirely reversible.
Over the last few years, cardiac magnetic resonance (CMR) for patients with AS has emerged and given us remarkable insights into the myocardial response, which has been found to be heterogeneous and sex-specific. 7 CMR with late gadolinium enhancement imaging allows visualization and quantification of myocardial fibrosis (MF) unlike any other clinical tool, with reliable precision and prognostic capabilities, over and above traditional predictors such as age, LV ejection fraction, and echocardiographic measures of AS severity. LV hypertrophy comes at a cost of increased MF, which can be divided into 2 types: diffuse reactive fibrosis, which tends to be associated with heightened interstitial collagen deposition and is potentially reversible with AVR, and replacement fibrosis, which is not reversible and is independently associated with poor outcomes. A recent TAVR expert consensus has, in fact, suggested the use of CMR in the evaluation of MF and for the identification of other cardiomyopathies. 8 Nonetheless, given the traditional reliance on bedside assessments and echocardiography, as well as the required expertise and relative less availability, the incorporation of CMR into routine clinical practice and decision-making for AS remains limited in scope.
In this issue of Circulation, Musa and colleagues 9 from 6 cardiothoracic surgical centers in the United Kingdom present the findings from a large, multicenter registry (British Society for Cardiovascular Magnetic Resonance Valve Consortium) that included 674 patients with severe AS who received either surgical AVR or TAVR after a CMR study. Of note, the CMR study was prospectively performed for research purposes, not for clinical indications. Although a retrospective analysis, this was a well-conducted collaborative study with high standards in methodology, which included both independent core laboratory analysis of each individual CMR parameter and blinded adjudication of events. There are 3 key findings. First, preoperative MF is common, with 51% of the cohort affected, and was predominantly nonischemic in origin (65% nonischemic versus 35% ischemic). Patients with MF had a more advanced AS phenotype with worse symptoms, greater rates of myocardial infarction, more LV hypertrophy, and lower LV ejection fraction. Second, regardless of the aortic valve intervention (surgical AVR or TAVR), the presence of MF was independently associated with a 2-fold higher rate of all-cause mortality and a 3-fold higher rate of cardiac death over a median follow-up of only 3.6 years. This hazard was evident for both ischemic and nonischemic types. Finally, the risk of MF was not just binary (ie, present versus absent) but dose-dependent. For every 1% increase in MF, all-cause and cardiovascular mortality increased by 11% and 8%, respectively. 9 The findings of Musa et al 9 certainly are provocative, and they reflect the prognostic importance of the ventricular response to AS. Early subclinical alterations in the myocardial architecture are known to occur in AS, even before the valvular lesion is severe, and we need both an ability to detect these changes and a greater understanding of their implications. Moreover, these findings support the mechanistic concept that once MF is established by CMR, there is the potential for progression and even irreversibility despite AVR. 10 Although increased attention has been given to identifying markers of futility of AVR in AS, we believe significant caution should be exercised if one is considering denying AVR to patients on the basis of worse survival from MF after therapy. MF is very common in AS, comparative data on medical management versus AVR are not available, and AVR is a potentially lifesaving therapy that relieves heart failure for many patients. Although certainly prognostic, the increases observed by Musa et al 9 in all-cause mortality of 11% per 1% increase in late gadolinium enhancement are relative and not absolute. The most notable aspect of the present study is the opportunity to identify patients who would benefit from AVR, earlier than the traditional metric of symptoms, and perhaps before adverse ventricular remodeling becomes irreversible. The field has sought the use of such clinical markers in asymptomatic patients previously (eg, LV hypertrophy, nonsustained ventricular tachycardia, abnormal exercise testing, blood biomarkers), but they have never been fully embraced, with none having Class I recommendations in current practice guidelines. The findings of Musa et al 9 describe gradations of MF associated with gradations of risk. These findings might be extrapolated to imply that timely detection of small amounts of MF could be important and could be a marker for future progression and a poor prognosis that would herald consideration for AVR in patients without "traditional" indications.
Two prospective multicenter randomized controlled trials, EVOLVED-AS (Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS; NCT03094143) and EARLY-TAVR (Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis; NCT03042104), are currently evaluating the hypothesis that early intervention with AVR will yield better outcomes (all-cause mortality, unplanned cardiovascular hospitalization) compared with a watchful waiting strategy for asymptomatic patients with severe AS. Although the decision for aortic valve intervention versus observation in EVOLVED-AS is driven by CMR identification of MF, the choice in EARLY-TAVR occurs regardless of the CMR findings. Together, these 2 studies will provide complementary findings and much-needed clarity to this field to better guide shared decision-making. Equally important will be longterm follow-up for vigilance of valve durability and the impact of other potential complications (ie, thrombosis, endocarditis, pacemaker), which could result from choosing this early intervention approach.
Although one could in theory personalize the approach of safe watchful waiting versus early aortic valve intervention, the reality is that there is an incredible heterogeneity in disease presentation and progression. 11, 12 Furthermore, not all MF is related to severe AS but rather in most circumstances is multifactorial. The importance of arterial stiffness and systemic pulsatile arterial load on MF, particularly in elderly patients receiving TAVR, cannot be underestimated in the older population. 13 In addition, CMR has other utility for the aging cardiovascular system, with increased recognition of common disease overlap of patients with AS with wild-type transthyretin cardiac amyloidosis, which has raised questions about futility.
14 Evidence of cardiac amyloidosis with CMR or bone scintigraphy can better inform and frame shared decision-making discussions about expectations before and after interventions.
Great progress has been made to create safer treatment strategies for patients with AS, and we now need to better explore efforts for early diagnosis of adverse findings, whether they are overt or subclinical, that could lead to beneficial referral to valvular heart care centers, ideally before the progression of AS renders our available treatment methods "too little, too late." The remarkable work by Musa and colleagues 9 highlights this possibility through emphasizing the importance of early examination of the ventricular response expressed as MF detected on CMR imaging. If findings of MF can be used to detect early and important consequences, can be used as a disease modifier, or can help stave off heart failure, then the decisions about if, when, and how to intervene may become easier and to the benefit of many patients.
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